Case Study: HRT and Antidepressant Prescribing Review

 

Work Completed

  • 150 female patients co-prescribed HRT and a first-line antidepressant were identified and reviewed.
  • Individual clinical assessments were conducted to determine appropriateness of dual therapy.
  • 52 patients were excluded as not clinically appropriate for intervention.
  • 97 patients were invited for a structured medication review with the Medicines Management Team.
  • Patients were contacted via SMS and offered consultations to consider deprescribing.
  • Additional support offered included referral to our Health Connections team, lifestyle advice, and our 6 week Habits for Health programme.
 

Key Results

  • 53 out of 97 patients (56%) reduced or stopped their antidepressant following review.
  • 44 out of 97 patients (44%) declined intervention.
  • 18 patients accepted referral for lifestyle and wellbeing support.
  • A proportion of patients were identified where symptoms may have been menopause-related or due to underlying physical health conditions rather than primary mental health diagnoses.
 

Annual Impact

  • Cost saving: £578.76 per year
  • Carbon saving: 90 kg CO₂e per year
  • Carbon equivalent: ~475 km of car travel
 

Learning Points

  • Menopausal symptoms can mimic anxiety and depression, therefore consider hormonal causes before initiating antidepressants.
  • Review ongoing need for antidepressants when HRT is started.
  • Holistic assessment (including blood tests where appropriate) is essential to rule out underlying conditions (e.g. thyroid dysfunction, B12 deficiency).
  • Medication reviews are key opportunities to identify deprescribing potential.
  • SMS invitations and structured reviews are effective tools for engaging patients.
  • Deprescribing contributes to both financial and environmental sustainability within the NHS.
  • This approach could be applied to other areas where antidepressants may be prescribed for alternative underlying causes.